Status:
COMPLETED
Bevacizumab and Vasoconstriction
Lead Sponsor:
Radboud University Medical Center
Conditions:
Hypertension
Cancer
Eligibility:
MALE
18-50 years
Phase:
NA
Brief Summary
Rationale: The introduction of angiogenesis inhibitors has remarkably improved treatment of patients with several types of cancer. One of the most common side effects of angiogenesis inhibitors is hyp...
Eligibility Criteria
Inclusion
- Male 18-50 years old
- normal results of glucose, lipids and creatinine
- informed consent
Exclusion
- History of abuse of drugs or alcohol
- History of malignant disease
- First degree relatives with a history of cancer before the age of 50
- First degree relatives with a history of premature cardiovascular disease
- Current use of medication
- Clinical evidence of cardiac of pulmonary disease
- Hypertension ( systolic\>140mmHg, diastolic \>90mmHg)
- Diabetes mellitus
- smoking
- a history of thombosis or a family history of recurrent thrombosis
- abnormality on ECG
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00929058
Start Date
June 1 2009
End Date
November 1 2009
Last Update
May 18 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500